The Union Budget has unveiled a major push for India’s biopharmaceutical sector through a new initiative called BioPharma SHAKTI, backed by an outlay of ₹10,000 crore over five years. The government wants to help India move beyond making low-cost generic medicines and become a global hub for advanced biological drugs and biosimilars. These are complex medicines made from living systems and are increasingly critical for treating diseases like cancer, diabetes, and autoimmune disorders.
The announcement signals a strategic shift in India’s healthcare and industrial policy, linking public health needs with innovation, education, and global competitiveness.
What BioPharma SHAKTI Is About
BioPharma SHAKTI aims to build a complete ecosystem for the domestic production of biologics and biosimilars. Presenting the proposal in Parliament, Nirmala Sitharaman described the programme as part of the government’s effort to scale up seven strategic and frontier sectors.
Biopharmaceuticals differ from conventional chemical drugs. They are produced using living systems such as microorganisms, plant cells, or animal cells. Because of their complexity, they require advanced research infrastructure, skilled manpower, strong regulation, and reliable clinical trial systems. BioPharma SHAKTI seeks to address all these components together rather than in isolation.
Why the Timing Matters for Public Health
India’s disease burden is changing rapidly. Non-communicable diseases like cancer, diabetes, and autoimmune conditions are rising across age groups. These illnesses often require long-term treatment with biologic medicines, which remain expensive and largely imported.
Government advisors have pointed out that strengthening domestic capacity can reduce dependence on imports and improve access to life-saving therapies. By encouraging local production, the policy also aims to bring down costs and improve availability within the public health system.
Building Talent Through New Institutions
A key pillar of the strategy is education and research capacity. The Budget proposes to set up three new National Institutes of Pharmaceutical Education and Research under National Institute of Pharmaceutical Education and Research, while upgrading seven existing NIPERs.
These institutes play a critical role in training scientists, regulatory experts, and industry professionals. Officials associated with pharmaceutical education reforms have stressed that India cannot lead in biologics without a steady pipeline of highly trained researchers and regulators.
The expansion aims to reduce skill gaps and align academic training with emerging industry needs.
Strengthening Clinical Trials and Research Networks
Another major component is the creation of a network of over 1,000 accredited clinical trial sites across the country. Clinical trials are essential for testing the safety and effectiveness of new biologic drugs, yet India has historically lagged behind in large-scale, globally compliant trials.
Health policy experts involved in regulatory consultations note that a stronger clinical trial ecosystem will not only help domestic companies but also attract global research partnerships. This can position India as a preferred destination for ethical, cost-effective, and high-quality clinical research.
Regulation at Global Standards
The Budget also proposes to strengthen the Central Drugs Standard Control Organisation by creating a dedicated scientific review cadre and specialist workforce. Faster and more predictable regulatory approvals are crucial for biologics, which involve complex manufacturing and safety assessments.
Senior officials familiar with regulatory reforms have stated that aligning approval timelines with global benchmarks will improve industry confidence and patient access. A science-led regulatory system also enhances India’s credibility in international markets.
Industry Response and Economic Implications
Leaders from the pharmaceutical industry have welcomed the initiative. Satish Reddy, Chairman of Dr. Reddy’s Laboratories, described the programme as an enabler for India’s transition from volume-based production to high-value innovation.
Similarly, Winselow Tucker, President and General Manager of Eli Lilly and Company (India), highlighted the importance of predictable, science-driven regulation for bringing advanced therapies to patients faster.
Credit analysts like Anuj Sethi of Crisil Ratings have noted that while India has excelled in small-molecule generics, biosimilars represent the next frontier for sustainable growth and global relevance.
Understanding Biopharmaceuticals in Simple Terms
According to definitions followed by regulators such as the U.S. Food and Drug Administration, biological products are large, complex molecules made using biotechnology. They are harder to characterise and manufacture than conventional drugs, which makes regulatory oversight and quality control especially important.
This complexity explains why targeted government support is necessary. Without public investment and regulatory reform, private players alone may struggle to scale safely and competitively.
The Social Dimension: Access, Affordability, and Equity
Beyond industry growth, BioPharma SHAKTI carries a strong social dimension. Affordable access to biological medicines can significantly improve quality of life for patients with chronic and life-threatening conditions.
Public health experts argue that domestic production can support government health programmes by reducing procurement costs. It also creates high-skill jobs in research, manufacturing, quality control, and regulation, contributing to inclusive economic development.
At the same time, civil society groups stress that patient safety, ethical trials, and transparency must remain central as the sector expands.
Challenges Ahead
Despite its promise, the initiative faces challenges. Building biologics infrastructure requires sustained funding, inter-ministerial coordination, and close collaboration between academia, industry, and regulators. Delays in approvals, uneven state-level capacity, and global competition could test implementation.
Policy analysts have noted that success will depend on execution over the full five-year period, not just initial announcements.
Key Highlights of BioPharma SHAKTI
- ₹10,000 crore allocated over five years for biopharma development
- Focus on domestic production of biologics and biosimilars
- Three new NIPERs and upgrades to seven existing institutes
- Network of 1,000+ accredited clinical trial sites
- Stronger CDSCO with specialist scientific review capacity
Looking Ahead
BioPharma SHAKTI reflects India’s ambition to link healthcare needs with innovation-driven growth. If implemented well, it can reduce treatment costs, improve patient access, and position India as a trusted global biopharma hub.
The initiative marks a move from incremental reform to ecosystem-level planning. Its real success will be measured not only in exports and investments, but in how effectively advanced medicines reach Indian patients while maintaining the highest standards of safety and science.
Clear Cut Research Desk
New Delhi, UPDATED: Feb 03, 2026 05:00 IST
Written By: Nidhi Chandrikapure
